For research purposes only — not for human consumption — 18+ only
Weight Loss
Retatrutide 30mg
$200.00
Research-grade Retatrutide 30mg vial. Triple agonist activity across GLP-1 GIP and glucagon receptors.
Use the peptide calculator to determine exact reconstitution volumes and dosing schedules for your research protocol.
Open Peptide Calculator ↗Retatrutide 30mg — the highest-dose vial of LY3437943 for comprehensive research programmes. This vial provides sufficient compound for multi-arm dose-response studies or extended animal model experiments using Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist. Phase II data showing 24.2% weight reduction at 48 weeks positions retatrutide as the most effective metabolic peptide compound currently in clinical development.
Molecular Data
Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3
Triple Receptor Mechanism
Acts simultaneously on GLP-1, GIP (at 8.9× endogenous potency), and glucagon receptors. The triple mechanism produces synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure through three independent pathways — superior to single or dual agonist approaches.
Clinical Evidence
Phase II obesity trial: 17.5% mean weight loss at 24 weeks, 24.2% at 48 weeks at 12mg weekly dosing. Significant secondary improvements in lipid profiles, glycaemic control, blood pressure, and hepatic steatosis. Phase III TRIUMPH trials ongoing.
High-Volume Research
The 30mg vial is suited to comprehensive research programmes requiring larger quantities, including full dose-response curves from low to high dose, parallel treatment arms, or multi-tissue pharmacodynamic studies.
Future Research
Phase III TRIUMPH trials ongoing. Research extends to type 2 diabetes, MASLD, cardiovascular risk, and renal disease models.
Reviews
There are no reviews yet.